Dominion Energy Inc vs GSK plc — how do they compare? Dominion Energy Inc trades at $61.75 (market cap $54.12B), while GSK plc trades at $46.65 (market cap $95.18B). The key difference: GSK plc is the larger of the two by market cap, and Dominion Energy Inc pays the higher dividend (4.34%). Which is the better fit depends on your goals — on Pluang, investors hold Dominion Energy Inc for 76 Days and GSK plc for 93 Days on average.
| D | GSK | |
|---|---|---|
Market Cap | $54.12B | $95.18B |
Volume | 4,249,753 | 5,852,596 |
Sector | Utilities | Health |
52-Week High | $71.67 | $61.18 |
52-Week Low | $57.08 | $43.24 |
Typical Hold Time | 76 Days | 93 Days |
Enterprise Value | $108.24B | $115.25B |
Dividend Yield | 4.34% | 3.86% |
Signals from Pluang's Aura AI — not financial advice
Dominion Energy (D) trades at $61.75, down 0.4% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The company reported strong Q2 2026 EPS of $0.79 versus $0.681 expected, continuing a pattern of exceeding expectations. Fundamentals show improving revenue growth to $16.51B in 2025 and net income margin expansion to 13.99%, though cash flow trends show significant capital investments. The pending merger with NextEra Energy dominates recent news coverage, with regulators reviewing a proposed $1 billion annual Virginia supplier program.
Dominion Energy presents a mixed investment case with solid fundamental performance offset by technical weakness and merger execution risks. The stock trades below analyst consensus target of $71.56, offering potential upside if the NextEra merger proceeds smoothly. Key risks include regulatory approval uncertainty, high capital expenditure requirements, and interest rate sensitivity given the company's substantial debt load of $37.31B long-term.
GSK trades at $47.02, up 0.9% today, with a bearish technical signal but strong fundamentals. The company reported revenue of $32.67B in 2025 with a net income margin of 14.52% and has beaten EPS estimates for three consecutive quarters. Recent news highlights strategic oncology investments and a $750M deal for a cancer therapy, signaling growth initiatives.
The outlook is mixed: solid profitability and a reasonable P/E of 15.1 support value, but technical indicators show bearish pressure near key support at $46. Risks include patent expirations and competitive pressures, while analyst sentiment is cautious with 31% buy ratings. Upside depends on pipeline execution and cost savings.
Trailing returns across standard periods
Latest headlines on both assets
Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion owns a liquefied natural gas export facility in Maryland and is constructing a 5.2 GW wind farm off the Virginia Beach coast.
Read more on D →In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →